Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
INFECTIOUS DISEASES / CLINICAL RESEARCH
Seroprevalence of hepatitis A virus, hepatitis B virus, hepatitis C virus, and syphilis among human immunodeficiency virus-infected people at a university hospital, Turkey
1
Ondokuz Mayis University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Samsun, Turkey
Submission date: 2019-09-10
Final revision date: 2020-02-04
Acceptance date: 2020-03-12
Online publication date: 2020-08-04
Publication date: 2025-04-23
Corresponding author
Heval Can Bilek
Ondokuz Mayis University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Korfez District, 55270, Atakum, Samsun, Turkey
Ondokuz Mayis University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Korfez District, 55270, Atakum, Samsun, Turkey
Arch Med Sci 2025;21(2):437-441
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Infections such as viral hepatitis and syphilis that share similar transmission routes with human immunodeficiency virus (HIV) may adversely affect the course of the disease. We aimed to determine the seroprevalence of viral hepatitis and syphilis among HIV-infected people at the initial stage of diagnosis.
Material and methods:
The medical records of 336 HIV-infected people aged 18 years and older, who were followed up between 2005 and 2018 at a university hospital in Samsun, Turkey, were evaluated retrospectively in terms of initial serological markers for viral hepatitis and syphilis.
Results:
Hepatitis B surface antigen (HBsAg) was positive in 13 (4.2%) of 303 patients, antibody to HBs antigen (anti-HBs) in 117 (39.2%) of 298 patients, antibody to hepatitis C virus (anti-HCV) in 3 (0.9%) of 301 patients, total antibody to hepatitis B core antigen (anti-HBc total) in 70 (29.2%) of 239 patients and total antibody to hepatitis A virus (anti-HAV total) in 224 (84.5%) of 265 patients. Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) was detected in one (12.5%) of 8 patients with isolated anti-HBc. Of 224 patients who were examined for syphilis, 34 (15.1%) were positive for Treponema pallidum hemagglutination (TPHA).
Conclusions:
In our study, high seroprevalence of syphilis and low immunity to HBV were detected. Health care facilities that follow up HIV-infected people should determine the serological profiles initially once the patients are diagnosed. It should be kept in mind that due to behavioral risk factors among HIV-infected people prevalence of coinfections may be higher than the rate in the community.
Infections such as viral hepatitis and syphilis that share similar transmission routes with human immunodeficiency virus (HIV) may adversely affect the course of the disease. We aimed to determine the seroprevalence of viral hepatitis and syphilis among HIV-infected people at the initial stage of diagnosis.
Material and methods:
The medical records of 336 HIV-infected people aged 18 years and older, who were followed up between 2005 and 2018 at a university hospital in Samsun, Turkey, were evaluated retrospectively in terms of initial serological markers for viral hepatitis and syphilis.
Results:
Hepatitis B surface antigen (HBsAg) was positive in 13 (4.2%) of 303 patients, antibody to HBs antigen (anti-HBs) in 117 (39.2%) of 298 patients, antibody to hepatitis C virus (anti-HCV) in 3 (0.9%) of 301 patients, total antibody to hepatitis B core antigen (anti-HBc total) in 70 (29.2%) of 239 patients and total antibody to hepatitis A virus (anti-HAV total) in 224 (84.5%) of 265 patients. Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) was detected in one (12.5%) of 8 patients with isolated anti-HBc. Of 224 patients who were examined for syphilis, 34 (15.1%) were positive for Treponema pallidum hemagglutination (TPHA).
Conclusions:
In our study, high seroprevalence of syphilis and low immunity to HBV were detected. Health care facilities that follow up HIV-infected people should determine the serological profiles initially once the patients are diagnosed. It should be kept in mind that due to behavioral risk factors among HIV-infected people prevalence of coinfections may be higher than the rate in the community.
REFERENCES (54)
1.
Trickey A, May MT, Vehreschild JJ, et al. The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017; 4: e349-e56.
2.
Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (1 Suppl): S6-S9.
3.
Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006; 57: 815-8.
4.
Feld JJ, Ocama P, Ronald A. The liver in HIV in Africa. Antiretrovir Ther 2005; 10: 953-65.
5.
Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11: 597-606.
6.
Soriano V, García-Samaniego J, Valencia E, Rodríguez- Rosado R, Muñoz F, González-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 1-4.
7.
Soriano V, Martín-Carbonero L, García-Samaniego J, Puoti M. Mortality due to viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 33: 1793-4.
8.
Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
9.
Lynn WA, Lightman S. Syphilis and HIV: a dangerous combination. Lancet Infect Dis 2004; 4: 456-66.
10.
Ho LE, Lukehart AS. Syphilis: using modern approaches to understand an old disease. J Clin Invest 2011; 121: 4584-92.
11.
Kassutto S, Sax P. HIV, and syphilis co-infection: trends and interactions. AIDS Clin Care 2003; 15: 9-18.
12.
Ural S, Kaptan F, Türker N, et al. Seroprevalence of hepatitis B virus and hepatitis C virus infections in human immunodeficiency virus-infected patients. Klimik Derg 2010; 23: 100-4.
13.
Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49 (5 Suppl): 138-45.
14.
Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7: 402-9.
15.
Mistik R, Balik I. Epidemiology of viral hepatitis in Turkey: a meta-analysis. In: Kilicturgay K (ed.). Viral hepatitis 98. 1st ed. Ankara: Viral Hepatitle Savasim Dernegi; 1998, p. 10-39.
16.
Emekdas G, Cavuslu S, Oncul O, Artuk C. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol 2006; 21: 299-305.
17.
Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe – a review. Euro Surveill 2008; 13: 18880.
18.
Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; 21: 1020-6.
19.
Tosun S. Epidemiology of viral hepatitis in Turkey: a meta-analysis of all published papers. In: Tabak F, Tosun S (eds.). Viral Hepatit 2013. Ankara: Viral Hepatitle Savaşım Derneği; 2013, p. 27-79.
20.
Thomas DL, Mahley RW, Badur S, Palaoglu E, Quinn TC. The epidemiology of hepatitis C in Turkey. Infection 1994; 22: 411-4.
21.
Aygen B, Demirtürk N, Türker N, et al. Management of chronic hepatitis C Virus Infection: a consensus report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases – 2017 Update. Klimik Derg 2017; 30 (Suppl 1): 2-36.
22.
Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 797-808.
23.
Aydin OA, Yemisen M, Karaosmanoglu HK, et al. Low prevalence of hepatitis C virus infection among hiv-positive patients: data from a large-scale cohort study in Istanbul, Turkey. Hepat Mon 2014; 14: e18128.
24.
Sayan M, Ozguler M, Sarigul Yildirim F, et al. Molecular determining of HIV-1 with the presence of hepatitis B virus and hepatitis C virus co-infections. Abstract Supplement HIV Glasgow 2018 J Int AIDS Soc 2018; 21(S8): e25187.
25.
Spradling PR, Richardson JT, Buchacz K, et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr 2010; 53: 388-96.
26.
Yemisen M, Aydın OA, Gunduz A, et al. Epidemiological profile of naive HIV-1/AIDS patients in Istanbul: the largest case series from Turkey. Curr HIV Res 2014; 12: 60-4.
27.
Dokuzoguz B, Korten V, Gokengin D, et al. Transmission route and reasons for HIV testing among recently diagnosed HIV patients in HIV-TR cohort, 2011-2012. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19595.
28.
Dökmetaş İ. Epidemiology and pathogenesis of HAV infection. In: Tabak F, Balık İ, Tekeli E (eds.). Viral Hepatit 2007. 1. Baskı. İstanbul: Viral Hepatitle Savaşım Derneği; 2007: 51-60.
29.
Thio CL, Seiberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-6.
30.
Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118 Suppl 10A: 75S-83S.
32.
Centers for Disease Control and Prevention (CDC). Hepatitis A. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook. 13th ed. Hamborsky J, Kroger A, Wolfe S (eds.). Public Health Foundation, Washington, DC2015 [accessed July 2019].
33.
Ministry of Health General Directorate of Public Health Department of Infectious Diseases, Turkey. HIV-AIDS Diagnosis and Treatment Guide. https://hsgm.saglik.gov.tr/dep... [2019, accessed 10 July 2019].
34.
Sofian M, Aghakhani A, Izadi N, et al. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. Int J Infect Dis 2010; 14: 308-10.
35.
Alhababi F, Sallam TA, Tong CY. The significance of ‘anti-HBc only’ in the clinical virology laboratory. J Clin Virol 2003; 27: 162-9.
36.
Pondé RA, Cardoso DD, Ferro MO. The underlying mechanisms for the ‘anti-HBc alone’ serological profile. Arch Virol 2010; 155: 149-58.
37.
Altunay H, Kenar S, Koçak N, Cavuşlu Ş. The investigation of HBV infectiousity in isolated Anti-HBc seropositivity. Viral Hepatit Derg 2003; 8: 10-5.
38.
Bal SH, Heper Y, Kumaş LT, Mistik R, Töre O. Investigation of the presence of HBV-DNA in isolated anti-HBc positive cases and their importance in blood banking. Mikrobiyol Bul 2009; 43: 243-50.
39.
Tas T, Kaya S, Onal S, Kucukbayrak A. The detection of HBV DNA with polymerase chain reaction in blood donors with isolated hepatitis B core antibody. Med Glas (Zenica) 2012; 9: 227-30.
40.
Santos EA, Yoshida CF, Rolla VC, et al. Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2003; 22: 92-8.
41.
Osborn MK, Guest JL, Rimland D. Hepatitis B and HIV coinfection: relation of different serological patterns to survival and liver disease. HIV Med 2007; 8: 271-9.
42.
Pérez-Rodríguez MT, Sopeña B, Crespo M, et al. Clinical significance of “anti-HBc alone” in human immunodeficiency virus-positive patients. World J Gastroenterol 2009; 15: 1237-42.
43.
Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20: 1253-60.
44.
Karaosmanoğlu HK, Mete B, Gunduz A, et al. Serological profiles of HBV among HIV-infected patients in Istanbul, Turkey. Int J Clin Case 2018; 2: 44-7.
45.
Farhi D, Dupin N. Management of syphilis in the HIV-infected patient: facts and controversies. Clin Dermatol 2010; 28: 539-45.
46.
Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect 2011; 87: 183-90.
47.
Erol S, Altoparlak İÜ, Özkurt Z, Yer A. Seroprevalence of HBsAg, anti-HCV, anti-HIV non-Treponemal syphilis antibodies in blood donors in Erzurum region. J Turk Microbiol Soc 2001; 31: 245-9.
48.
Aydinli A, Coskun D, Aytac J. Evaluation of routine screening results of blood donors in Florence Nightingale Hospital for a seven-year period. Mikrobiyol Bul 2006; 40: 143-5.
49.
Agacfidan A, Badur S, Gerikalmaz Ö. Syphilis prevalence among unregistered prostitutes in Istanbul. Turk J Infect 1994; 8: 143-5.
50.
Aydin ÖA, Karaosmanoglu HK, Sayan M, Ince ER, Nazlican Ö. Seroprevalence and risk factors of syphilis among HIV/AIDS patients in Istanbul, Turkey. Cent Eur J Public Health 2015; 23: 65-8.
51.
Alp E, Bozkurt I, Doğanay M. Epidemiological and clinical characteristics of HIV/AIDS patients followed-up in Cappadocia region: 18 years’ experience. Mikrobiyol Bul 2011; 45: 125-36.
52.
Kaptan F, Örmen B, Türker N, et al. Retrospective evaluation of 128 cases infected with human immunodeficiency virus. Turkiye Klinikleri J Med Sci 2011; 31: 525-33.
53.
Novak RM, Ghanem A, Hart R, et al. Risk factors and incidence of syphilis in human immunodeficiency virus (HIV)-infected persons: the HIV Outpatient Study, 1999-2015. Clin Infect Dis 2018; 67: 1750-9.
54.
HIV/AIDS surveillance in Europe 2019 – 2018 data. https://www.ecdc.europa.eu/sit.... [2019, accessed: 10 July 2019].
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
